10-Q: Kewaunee Scientific Reports Strong Sales Growth, Nu Aire Integration

Kewaunee Scientific Corporation announced significant revenue growth for the quarter and six months ended October 31, 2025, driven by the Nu Aire acquisition and international project deliveries, despite a quarterly dip in net earnings.

Summary

• Net sales for the three months ended October 31, 2025, increased by 46.7% to $70.1 million, up from $47.8 million in the prior year period.
• Domestic sales rose 51.7% to $55.2 million, primarily due to the Nu Aire acquisition completed on November 1, 2024.
• International sales grew 31.0% to $14.9 million, driven by continued delivery of large projects.
• Net earnings attributable to Kewaunee Scientific Corporation decreased by 18.7% to $2.4 million ($0.82 diluted EPS) for the three months, compared to $3.0 million ($1.01 diluted EPS) in the prior year period.
• For the six months ended October 31, 2025, net sales increased 46.8% to $141.2 million, and net earnings attributable to Kewaunee Scientific Corporation increased 6.5% to $5.5 million ($1.86 diluted EPS).
• Gross profit margin for the three months was 28.1%, down from 29.2% in the prior year period, impacted by the Nu Aire acquisition, lower domestic manufacturing volumes, and reduced productivity.
• Operating expenses for the three months increased 64.0% to $15.6 million, primarily due to the Nu Aire acquisition and higher SG&A wages, benefits, incentive, and stock-based compensation.
• Interest expense surged 140.0% to $1.1 million for the three months, reflecting increased borrowings and interest rates.
• Order backlog stood at $192.9 million as of October 31, 2025, compared to $184.4 million at October 31, 2024, and $214.6 million at April 30, 2025.
• The company completed the repayment of its $23.0 million subordinated Seller Notes on December 4, 2025, partially funded by an additional $10.0 million term loan from PNC Bank.

Sentiment

Score: 6

Explanation: The company demonstrates strong revenue growth and a healthy backlog, indicating solid market demand and strategic expansion through acquisition. However, the quarterly decline in net earnings and significant increase in operating and interest expenses highlight profitability pressures and integration costs. The repayment of seller notes is a positive, but it required additional debt, suggesting a mixed financial picture with both growth opportunities and cost challenges.

Positives

• Significant net sales growth of 46.7% for the quarter and 46.8% for the six months, driven by the strategic Nu Aire acquisition and strong international project deliveries.
• International sales increased by 31.0% for the quarter and 30.5% for the six months, indicating robust demand in foreign markets.
• Gross profit for the six months ended October 31, 2025, increased by 53.7% to $40.7 million, and gross profit margin improved to 28.8% from 27.5% in the prior year period.
• Net earnings attributable to Kewaunee Scientific Corporation increased by 6.5% for the six months ended October 31, 2025, reaching $5.5 million.
• Diluted EPS for the six months increased by 6.3% to $1.86.
• Order backlog remains strong at $192.9 million, near record levels, indicating future revenue visibility.
• Working capital improved to $67.8 million at October 31, 2025, from $64.7 million at April 30, 2025, and the current ratio improved to 2.5-to-1.0 from 2.2-to-1.0.
• Successful integration of Nu Aire, which contributed $19.4 million in revenue and $1.1 million in net earnings for the three months ended October 31, 2025.
• Repayment of the $23.0 million Seller Notes on December 4, 2025, eliminating a significant subordinated debt obligation.

Negatives

• Net earnings attributable to Kewaunee Scientific Corporation decreased by 18.7% for the three months ended October 31, 2025, to $2.4 million.
• Diluted EPS for the three months decreased by 18.8% to $0.82.
• Gross profit margin for the three months ended October 31, 2025, declined to 28.1% from 29.2% in the prior year period, attributed to lower domestic manufacturing volumes and reduced productivity.
• Operating expenses increased significantly by 64.0% for the three months and 63.3% for the six months, outpacing sales growth and impacting profitability.
• Interest expense more than doubled for both the three and six-month periods, reflecting higher debt levels and interest rates.
• Net cash provided by operating activities decreased substantially to $1.5 million for the six months ended October 31, 2025, from $7.6 million in the prior year period.
• Increased capital expenditures, with net cash used in investing activities rising to $2.3 million from $1.0 million in the prior year period.

Risks

• Ability to realize the anticipated benefits from the Nu Aire acquisition.
• Impact of competitive and general economic conditions, including disruptions from government mandates, supplier constraints, and other supply disruptions, both domestically and internationally.
• Changes in customer demands and technological advancements in operations or the industry.
• Dependence on customers' required delivery schedules.
• Fluctuations in operating results from quarter to quarter.
• Risks associated with international operations, including foreign currency fluctuations.
• Changes in the legal and regulatory environment.
• Volatility in raw materials and commodity costs, such as steel, wood, and epoxy resin.
• Potential impacts from acts of terrorism, war, governmental action, natural disasters, and other Force Majeure events.

Future Outlook

The company's ability to predict future demand is limited due to its role as a subcontractor or supplier, with demand dependent on laboratory construction projects. Earnings are sensitive to fluctuations in project pricing and raw material costs. Second-quarter results for fiscal year 2026 align with expectations of project delivery timeline volatility. However, quoting and booking activity remain strong, reflected in a near-record backlog. The company is focused on organic and inorganic growth, making strategic investments in people, processes, and technology to support sustainable growth and manage short-term headwinds while maintaining long-term business health.

Management Comments

• The acquisition of Nu Aire expands our capabilities, allowing the combined organization to better meet the diverse needs of end-users in laboratory furnishings.
• Nu Aire's established distribution partners in regions where we have not previously had a presence accelerate our vision of becoming the market leader in the design and manufacturing of laboratory furniture and technical products.
• Our second quarter results for fiscal year 2026 align with the expectations previously communicated regarding volatility in project delivery timelines.
• Our quoting and booking activity remain strong, which is reflected in our backlog, which remains near record levels.
• We remain focused on growth, both organically and inorganically, and are committed to making strategic investments in the people, processes, and technology that will support and enable this growth in a sustainable manner.
• We are confident that these strategic investments and our healthy backlog position us well to handle any anticipated short-term headwinds and maintain the long-term health of the business.

Industry Context

The company operates in the specialized laboratory furnishings and technical products market, which is influenced by trends in life sciences, healthcare, education, and industrial sectors. The acquisition of Nu Aire, a manufacturer of biological safety cabinets and other essential laboratory equipment, positions the company to capitalize on the growing demand for advanced laboratory infrastructure and containment solutions. The strong international sales suggest a robust global market for laboratory construction and outfitting, while domestic performance is significantly boosted by strategic M&A.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Mixed impact with strong revenue growth and backlog, but quarterly earnings decline and increased debt. The repayment of seller notes could be seen positively for debt structure.
• Employees: Integration of Nu Aire implies potential changes and opportunities within the combined workforce. Increased SG&A wages and benefits suggest investment in personnel.
• Customers: Expanded product portfolio and capabilities through Nu Aire acquisition aim to better meet diverse needs in laboratory furnishings.
• Creditors: Increased debt levels due to the Nu Aire acquisition and subsequent refinancing for seller note repayment, but the company remains in compliance with financial covenants.

Next Steps

• Continue evaluating the provisions of the One Big Beautiful Bill Act (OBBBA) to assess potential effects on the effective tax rate, deferred tax assets and liabilities, and future cash tax obligations.
• Continue integrating Nu Aire into the company's systems and control environment.
• Adopt ASU 2023-09 (Income Tax Disclosures) for annual reporting in fiscal year 2026.
• Adopt ASU 2024-03 (Expense Disaggregation Disclosures) for annual disclosures in fiscal year 2028 and interim disclosures in fiscal year 2029.
• Focus on organic and inorganic growth, making strategic investments in people, processes, and technology.

Key Dates

Recommendation

The company exhibits strong top-line growth driven by a strategic acquisition and robust international demand, reflected in a healthy backlog. This indicates a positive long-term trajectory. However, the quarterly decline in net earnings, significant increase in operating expenses, and higher interest burden suggest short-term profitability challenges and integration costs. While the repayment of seller notes is a positive step in debt management, it involved taking on new term loan debt. Given the mixed short-term performance against strong long-term indicators and strategic moves, a 'hold' recommendation is appropriate, awaiting clearer signs of sustained profitability improvement and successful integration without further significant margin erosion.

Keywords

Laboratory Furnishings, Scientific Equipment, Nu Aire Acquisition, SEC 10-Q, Financial Results, Laboratory Construction, Biotechnology Equipment, Healthcare Equipment, Research Facilities, Industrial Equipment